Mylan/Merck KGaA To Divest Five Generic Drugs To Clear Antitrust Hurdle For Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Amneal Pharmaceuticals is the beneficiary of FTC’s concerns about the sales power of the newly combined entity.
You may also be interested in...
Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products
The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.
Generic Paxil CR Will Launch By October 2008 Under GSK/Mylan Settlement
Mylan gains rights to market extended-release paroxetine in 12.5 mg, 25 mg and 37.5 mg doses.
Generic Paxil CR Will Launch By October 2008 Under GSK/Mylan Settlement
Mylan gains rights to market extended-release paroxetine in 12.5 mg, 25 mg and 37.5 mg doses.